A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers.
Feng J, Xiao X, Xia X, Min J, Tang W, Shi X, Xu K, Zhou G, Li K, Shen P, Bao R, Wu S, Lin M, Yuan K, Lian Z, Hu L, Li N, Wu Z, Zhai X, Liu X, Hu K, Wu J, Ding C, Zhao H, Gong X, Zhang S, Jin J, Li D, Liu M, Ye Y, Ma B, Guo RT, Zhang A, Pang X.
Feng J, et al. Among authors: bao r.
Cancer Cell. 2025 Jul 25:S1535-6108(25)00310-1. doi: 10.1016/j.ccell.2025.07.006. Online ahead of print.
Cancer Cell. 2025.
PMID: 40780213
Free article.